Search results
Showing 901 to 950 of 1515 results for patients and public
In development Reference number: GID-TA11590 Expected publication date: TBC
In development Reference number: GID-TA11813 Expected publication date: TBC
Nipocalimab for treating generalised myasthenia gravis [ID6562]
In development Reference number: GID-TA11492 Expected publication date: TBC
In development Reference number: GID-TA11776 Expected publication date: TBC
In development Reference number: GID-TA11869 Expected publication date: TBC
We are listening to your views on this Technology appraisal guidance. Comments close 19 February 2026.
Aficamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6668]
Awaiting development Reference number: GID-TA11877 Expected publication date: TBC
Awaiting development Reference number: GID-TA11847 Expected publication date: TBC
Evidence-based recommendations on new generation cardiac CT scanners (Aquilion ONE, Brilliance iCT, Discovery CT750 HD and Somatom Definition Flash) for cardiac imaging in people with suspected or known coronary artery disease in whom imaging is difficult with earlier generation CT scanners.
In development Reference number: GID-TA11499 Expected publication date: TBC
Awaiting development Reference number: GID-TA11281 Expected publication date: TBC
In development Reference number: GID-TA11644 Expected publication date: 22 October 2026
In development Reference number: GID-TA11766 Expected publication date: TBC
In development Reference number: GID-TA11342 Expected publication date: TBC
Awaiting development Reference number: GID-TA11724 Expected publication date: TBC
Resminostat for maintenance treatment of advanced mycosis fungoides or Sezary syndrome [ID6478]
Awaiting development Reference number: GID-TA11606 Expected publication date: TBC
In development Reference number: GID-TA11592 Expected publication date: TBC
In development Reference number: GID-TA11625 Expected publication date: TBC
Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over [ID6579]
In development Reference number: GID-TA11780 Expected publication date: TBC
In development Reference number: GID-TA11804 Expected publication date: 08 October 2026
Awaiting development Reference number: GID-TA11686 Expected publication date: TBC
In development Reference number: GID-TA11687 Expected publication date: TBC
This is the user guide for submission of evidence to the National Institute for Health and Care Excellence (NICE) as part of the single technology appraisal and highly specialised technologies evaluations process. It explains what information NICE requires and the format in which it should be presented
This quality standard covers care and support and services for children, young people and adults with a learning disability (or a learning disability and autism) and behaviour that challenges, and their families and carers. It describes high quality care in priority areas for improvement.
View quality statements for QS101Show all sections
Sections for QS101
- Quality statements
- Quality statement 1: Lead commissioner
- Quality statement 2: Annual health check
- Quality statement 3: Initial assessment of behaviour that challenges
- Quality statement 4: Named lead practitioner
- Quality statement 5: Involving families and carers
- Quality statement 6: Parent-training programmes
- Quality statement 7: Personalised daily activities
Awaiting development Reference number: GID-TA11216 Expected publication date: TBC
Awaiting development Reference number: GID-TA11219 Expected publication date: TBC
In development Reference number: GID-TA11199 Expected publication date: TBC
Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]
Awaiting development Reference number: GID-TA11303 Expected publication date: TBC
Eneboparatide for treating chronic hypoparathyroidism [ID6532]
In development Reference number: GID-TA11688 Expected publication date: TBC
In development Reference number: GID-TA11760 Expected publication date: TBC
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]
In development Reference number: GID-TA11116 Expected publication date: 29 July 2026
In development Reference number: GID-IPG10392 Expected publication date: TBC
Awaiting development Reference number: GID-TA10972 Expected publication date: TBC
In development Reference number: GID-TA11749 Expected publication date: 10 June 2027
In development Reference number: GID-TA11693 Expected publication date: TBC
In development Reference number: GID-TA11660 Expected publication date: TBC
Awaiting development Reference number: GID-TA11670 Expected publication date: TBC
In development Reference number: GID-TA11308 Expected publication date: TBC
In development Reference number: GID-TA11094 Expected publication date: TBC
In development Reference number: GID-TA11842 Expected publication date: TBC
In development Reference number: GID-TA11650 Expected publication date: TBC
Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]
Awaiting development Reference number: GID-TA10971 Expected publication date: TBC
In development Reference number: GID-TA11773 Expected publication date: TBC
Awaiting development Reference number: GID-TA11747 Expected publication date: 14 April 2027
Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive, unresectable, locally advanced or metastatic breast cancer in adults who have had trastuzumab and a taxane.
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)
Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected stage 2B and 2C melanoma in people 12 years and over.
Evidence-based recommendations on brigatinib (Alunbrig) for anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor.
In development Reference number: GID-HTE10072 Expected publication date: 19 November 2026
This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)
This guideline covers interventions in the acute stage of a stroke or transient ischaemic attack (TIA). It offers the best clinical advice on the diagnosis and acute management of stroke and TIA in the 48 hours after onset of symptoms.